Jul 2026· Cell Death and Disease· Vol 17· 0 citations· 61 references
Medicine
TL;DR
The findings uncover a novel LA-fuelled metabolic-epigenetic axis that promotes the H3K4me3-mediated PLOD1 upregulation, consequently fostering PCa aggressiveness and unveiling a potential therapeutic vulnerability.
Abstract
Prostate cancer (PCa) progression is strongly influenced by the metabolites available in the tumor microenvironment (TME), including lactic acid (LA), which is actively imported by PCa cells to boost mitochondrial metabolism and drive de novo collagen synthesis, sustaining increased malignancy. LA exploitation promotes the unbalance of tricarboxylic acid (TCA) cycle intermediates, particularly succinate and fumarate, well-known epigenetic modifiers for histone (de)methylation. Here, we show that the LA-induced increase in succinate levels affects the activating H3K4me3 methylation mark in PCa cells, promoting a pro-invasive phenotype. Notably, pharmacological targeting of H3K4me3 using OICR-9429 reduces LA-enhanced PCa cell invasiveness. Moreover, LA-induced H3K4me3 enrichment regulates the expression of procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1 (PLOD1), a key enzyme involved in collagen maturation. Genetic impairment of PLOD1 reduces the LA-driven invasive potential of PCa cells, thereby highlighting PLOD1 as a crucial epigenetically regulated mediator of tumor invasion. Overall, our findings uncover a novel LA-fuelled metabolic-epigenetic axis that promotes the H3K4me3-mediated PLOD1 upregulation, consequently fostering PCa aggressiveness and unveiling a potential therapeutic vulnerability.
This work identifies alanyl tRNA synthetase 1 (AARS1) as a clinically relevant driver of aggressive and recurrent BC and defines an AARS1 associated metabolic and epigenetic program in BC and nominate AARS1 targeting strategies as a direction for further therapeutic development.
Qin Yuan, Tianbao Song, Yipeng He et al.· Advancement of science· 0 citations
Hair follicle stem cells (HFSCs) reside in a relatively hypoxic niche and preferentially use glycolytic metabolism, but how metabolic adaptation is coupled to epigenetic regulation of HFSC function remains incompletely understood. Since oxidative phosphorylation produces more reactive oxygen species (ROS) than glycolys...
Guan-Yu Lin, Xue-Jun Ni, Lei Chen et al.· Experimental Cell Research· 0 citations
Mechanistic investigations demonstrated that NAT10 elevates MARK2 expression, activating the mTOR/HIF-1α/C-Myc signaling cascade, thereby promoting aerobic glycolysis in PCa cells, suggesting that targeting ac4C mRNA modifications may provide a novel therapeutic strategy for managing prostate cancer.
Yi-Ming Zhang, Jian Wang, Gan-Ping Wang et al.· Cancer Gene Therapy· 0 citations
ABSTRACT Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC). Here we identify histone H3K18 lactylation (H3K18la), induced by GEM‐driven lactate accumulation, as a key epigenetic mechanism of chemoresistance. H3K18la functions as a transcri...
Li-Jun Zhao, Jian-Zhong Cao, Wen-Yue Liu et al.· Advancement of science· 0 citations
These results uncover a metabolism-epigenetics–cell cycle interface that may represent a therapeutic vulnerability in EGFR-mutant LUAD and identify a glycolysis–H4K8la–GAS2L3 axis that drives noncanonical cell-cycle reprogramming independently of classical Cyclin–CDK activation, thereby promoting acquired osimertinib r...
Shu-Man Zhen, Xiaohui Bai, Shu-Tang Liu et al.· Cell Death Discovery· 0 citations
Activation of quiescent or extremely slow-cycling breast cancer stem-like cells (qsBCSCs) contributes to tumor progression, yet the regulatory mechanisms involved in triple-negative breast cancer (TNBC) remain elusive. We developed a dual-reporter system combining NANOG-EGFP and H2B-mCherry pulse-chase labeling to sepa...
Shuai Liu, Yunfeng Ma, Yuanyuan Zeng et al.· Signal Transduction and Targ...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.